Payment overview · 2025
General Payments
$443.42
27 reported records · 9 companies
Healthcare provider profile · identity verified
Robert Scott Jacobs, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WAYCROSS, GA · NPI 1023015955
Verified facts
What the public records show
CMS Open Payments records show Robert Scott Jacobs, NP received $443.42 in general payments during 2025 across 27 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $86.70 | 19.6% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.27 | 15.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.90 | 13.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.61 | 11.2% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.98 | 10.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.92 | 10.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.16 | 7.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.52 | 6.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.36 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $443.42 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $69.27 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.61 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.90 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.98 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $45.92 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.88 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.16 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.16 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.52 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 75 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tramadol Hcl | Tramadol Hcl | 299 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 266 | 67 |
| Gabapentin | Gabapentin | 255 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 69 |
| Lisinopril | Lisinopril | 246 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 237 | 65 |
| Alprazolam | Alprazolam | 179 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 160 | 45 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 149 | 35 |
| Montelukast Sodium | Montelukast Sodium | 134 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 32 |
| Losartan Potassium | Losartan Potassium | 122 | 35 |
| Famotidine | Famotidine | 118 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 31 |
| Pregabalin | Pregabalin | 113 | 22 |
| Prednisone | Prednisone | 106 | 67 |
| Donepezil Hcl | Donepezil Hcl | 105 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 26 |
| Jardiance | Empagliflozin | 102 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 31 |
| Omeprazole | Omeprazole | 97 | 22 |
| Celecoxib | Celecoxib | 92 | 29 |
| Carvedilol | Carvedilol | 90 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 11 |
| Azithromycin | Azithromycin | 88 | 73 |
| Furosemide | Furosemide | 87 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 23 |
| Topiramate | Topiramate | 85 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 38 |
| Ezetimibe | Ezetimibe | 79 | 23 |
| Temazepam | Temazepam | 78 | suppressed |
| Meloxicam | Meloxicam | 77 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 14 |
| Metformin Hcl | Metformin Hcl | 75 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 75 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 20 |
| Potassium Chloride | Potassium Chloride | 73 | 22 |
| Buspirone Hcl | Buspirone Hcl | 69 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 22 |
| Sertraline Hcl | Sertraline Hcl | 68 | 13 |
| Januvia | Sitagliptin Phosphate | 67 | 17 |
| Trazodone Hcl | Trazodone Hcl | 66 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 20 |
| Alendronate Sodium | Alendronate Sodium | 60 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 17 |
| Ozempic | Semaglutide | 54 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 12 |
| Allopurinol | Allopurinol | 53 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 51 | 12 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 34 |
| Cefdinir | Cefdinir | 42 | 32 |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Linzess | Linaclotide | 42 | suppressed |
| Eliquis | Apixaban | 40 | suppressed |
| Lorazepam | Lorazepam | 40 | suppressed |
| Simvastatin | Simvastatin | 40 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 21 |
| Ibuprofen | Ibuprofen | 38 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 31 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 15 |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 21 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 16 |
| Ramipril | Ramipril | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $443.42 · 27 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, FARXIGA, Kerendia, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error